CRTX News and Press, Cortexyme Inc. From 10/19/20

-- Oral presentation at Clinical Trials on Alzheimer's Disease 2020 will include baseline characteristics of the Phase 2/3 GAIN Trial ahead of planned interim analysis expected to occur before year-end 2020 -- -- Poster at Society for Immunotherapy of Cancer Annual Meeting eva...

Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the disease. To treat Alzheimer's disease, it is probably necessary to slow down the production...

- Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind...

-- Presentation to be webcast on Cortexyme’s website -- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief ex...

  - New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388) - The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term extension of up to an additional five years Cortexyme, Inc. (Nasdaq...

Cortexyme (NASDAQ: CRTX ) : Q2 GAAP EPS of -$0.60 beats by $0.04 . More news on: Cortexyme, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

— GAIN Trial enrollment on track to complete in Q4 2020 — GAIN Trial interim analysis on schedule to complete by year end 2020 — Clinical pipeline expansion anticipated in 2021 Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pio...

Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation Mallinckrodt ( MNK ) stock moved up as the market responded to merger rumors for the company. While the name of the likely acquirer is kept under covers, the rumors have helped the company stock, which has seen...

Cortexyme (NASDAQ: CRTX ) announces that it has enrolled 500 subjects in its Phase 2/3 GAIN study evaluating lead candidate atuzaginstat (COR388) in patients with mild-to-moderate Alzheimer's disease. More news on: Cortexyme, Inc., Healthcare stocks news, Read more ...

- Open label extension is currently active for GAIN Trial completers in the United States with robust conversion of eligible patients - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollme...